Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 123,566

Document Document Title
WO/2017/042314A1
The present invention relates to methods and pharmaceutical composition for the treatment of post-traumatic epilepsies. In particular, the present invention relates to a method of treating post-traumatic epilepsy (PTE) in a subject in ne...  
WO/2017/042267A1
The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.  
WO/2017/043494A1
The purpose of the present invention is to provide a microcapsule, said microcapsule containing a biodegradable polymer and risperidone and having excellent sustained release properties, and a method for manufacturing the same. A microca...  
WO/2017/044571A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...  
WO/2017/044497A1
Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein t...  
WO/2017/044516A1
The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined ...  
WO/2017/043636A1
To provide a therapeutic agent for diseases associated with Nav 1.7, specifically diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, urinatio...  
WO/2017/044503A1
Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein t...  
WO/2017/041733A1
Provided is a polypeptide that inhibits Aβ protein aggregation of Alzheimer's disease, and an amino acid sequence thereof is Xaa1-Xaa2-Xaa3-Xaa4. Xaa1 and Xaa3 are identical amino acids and selected from I, V or L, Xaa2 is selected from...  
WO/2017/044575A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2...  
WO/2017/041711A1
The invention relates novel pharmaceutical use of kaurane compounds of formula (I) in treating and preventing cardiac hypertrophy and myocardium remodeling. The said compounds also can significantly ameliorate pulmonary hypertension and ...  
WO/2017/044002A1
The invention relates to the chemical and pharmaceutical industry and concerns the use of polyprenols of formula (1) to produce a drug, as well as the drug itself and a pharmaceutical composition containing compound (1) for the treatment...  
WO/2017/044502A1
Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment i...  
WO/2017/041680A1
Provided are a pharmaceutical composition of an amorphous vortioxetine or a salt thereof, and a preparation method therefor. The pharmaceutical composition comprises an amorphous vortioxetine or a pharmaceutically acceptable salt thereof...  
WO/2017/043092A1
The present invention relates to imidazolinone derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use ...  
WO/2017/042643A1
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds an...  
WO/2017/042567A1
This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in ...  
WO/2017/044569A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2...  
WO/2017/037166A1
The present invention relates to 1 -(4-(2-((1 -(3,4-difluorophenyl)-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1 -yl)ethanone salts, specifically to the hydrochloride and to the maleate, to pharmaceutical compositions comprising them, and ...  
WO/2017/041037A1
The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associat...  
WO/2017/038860A1
The present invention is: a free polyunsaturated fatty acid-containing composition, which comprises at least one C20 or higher free polyunsaturated fatty acid, the content being at least 80.0% of the fatty acids in the composition, and s...  
WO/2017/037812A1
The purpose of the present invention is to provide a patch preparation which uses a basic drug acid addition salt as a raw material and which has excellent skin permeability of the drug. This patch preparation is formed by providing an a...  
WO/2017/036397A1
Provided is a spray of ganoderma lucidum spore extract having undergone supercritical CO2 extraction.  
WO/2017/038925A1
The present invention addresses the problem of providing a pharmaceutical composition that has a high safety and with which the long-term stability can be ensured and the reduction in the amount of an active ingredient accompanying the o...  
WO/2017/037089A1
Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples ...  
WO/2017/039525A1
The invention relates to a method of treating a dopamine related disorder in a subject, the method comprises the steps of administering therapy to a subject, the therapy comprising a plurality of doses of levodopa over a selected time pe...  
WO/2017/035733A1
Provided are a conjugate of memantine and arctigenin, and a pharmaceutical composition comprising the conjugate. The conjugate can treat diseases associated with Aβ or Tau protein pathways, such as Alzheimer's disease or Parkinson's dis...  
WO/2017/040603A1
Described herein are dosing regimens and kits comprising (3R, 4R, 5S)-5-(difluoromethyl)piperidine-3.4-diol for the treatment and/or prevention of lysosomal storage disorders such as Gaucher disease. Also described are dosing regimens an...  
WO/2017/040611A1
An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L- theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).  
WO/2017/036436A1
The present invention provides primin derivatives of general formula II and/or III, wherein R1 is selected from the group consisting of methyl and hydrogen, R2 is selected from the group consisting of methoxy, hydroxy, hydrogen, R3 is se...  
WO/2017/040545A1
The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or method...  
WO/2017/037091A1
Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to stabilize or improve mood, modulate excessive emotional distress, reduce anxiety, and/or reduce stress. In an embodiment, the composition can be administered d...  
WO/2017/036118A1
An injectable Aripiprazole suspension preparation, comprising cellulose-based suspending agents and polyoxyethylene (20) Sorbitan Monooleate. Said suspension preparation has good stability, having an extended shelf life.  
WO/2017/036978A1
The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.  
WO/2017/037105A1
B. longum ATCC BAA-999, or a composition comprising B. longum ATCC BAA-999, for use in an individual to; support breastfeeding initiation and/or to optimise breastfeeding duration and/or to optimize the quality and/or quantity ofbreast m...  
WO/2017/040449A1
The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxi...  
WO/2017/040451A1
The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxi...  
WO/2017/037079A1
The invention relates to a 5H-dibenz[b,f]azepine-5-carboxamide derivative such as carbamazepine (CBZ) for use in a method for preventing or treating Andermann syndrome.  
WO/2017/038861A1
Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is a...  
WO/2017/040879A1
The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical diso...  
WO/2017/035631A1
The invention provides improved supplemental compositions, and methods for administering same to a user, for enhancing the onset, quality, and duration of sleep in humans and animals. The supplemental composition may contain a combinatio...  
WO/2017/038945A1
Provided is a therapeutic agent for diseases associated with the accumulation of abnormal substances in cells which contains, as an active ingredient, a substance for suppressing the expression of ERdj8, or a substance for suppressing an...  
WO/2017/036392A1
A derivative of inula lineariifolia lactone A, and in particular, a dimethylamine 4-O-acetyl inula lineariifolia lactone A or a salt thereof, preparation for same, and an application of same in preparation of medicine for treating multip...  
WO/2017/035801A1
A hericium erinaceus active substance, a preparation method for the active substance, and a pharmaceutical composition including the active substance. The active substance is prepared via the following steps: (a) placing a hericium erina...  
WO/2017/041054A1
Disclosed here are compositions and methods for preventing or treating certain health conditions associated with inflammation or oxidative stress. These compositions are prepared from ingredients containing phytochemicals that activate t...  
WO/2017/037661A1
The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions com...  
WO/2017/038656A1
The present invention provides: a novel tetrahydroazepine compound; and a method for producing the tetrahydroazepine compound. The present invention relates to: a tetrahydroazepine compound represented by general formula (10) (wherein R1...  
WO/2017/037813A1
The purpose of the present invention is to provide a transdermal absorption composition which has improved skin permeability of a basic drug, and a transdermal absorption promoter of a basic drug. This purpose is met by a transdermal abs...  
WO/2017/040877A1
The invention provides heterobicyclic pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's dise...  
WO/2017/036318A1
Provided are a 1,2,3,4-tetrahydroisoquinoline derivative having the structure of formula (I), a preparation method therefor and an application thereof. The compound of formula (I) may be used for the development of drugs for primary neur...  

Matches 401 - 450 out of 123,566